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ABSTRACT OF THESIS

MODULATION OF HIGH AFFINITY HORMONE BINDING TO LH/CG
RECEPTOR

Precise control of physiological phenomena is performed by various kinds of receptor
mediated signaling. The vast majority of receptors belong to the superfamily of G protein
coupled receptors (GPCRs), which form one of the largest protein families. In the
classical model of GPCR signaling, stimulation of seven transmembrane spanning GPCR
leads to the activation of heterotrimeric G proteins, which dissociate into α and βγ
subunits. The subunits activate effector molecules, which include second messenger
generating systems, giving rise to various kinds of cellular responses. The LH/CG
receptor is a member of the glycoprotein hormone receptor family along with the FSH
and TSH receptors, which belongs to the GPCR superfamily. Human chorionic
gonadotropin (hCG) binds to the exodomain of LH/CG receptor and the resulting hCGexodomain complex is thought to interact with the endodomain of the receptor to bring
about hormone signal.Unfortunately, little evidence is available for the precise hormone
contact points in the exo domain and endo domain of the receptor. The affinity of
hormone binding to the exodomain was enhanced when the endodomain was truncated.
This suggests that the endodomain modulates the hormone binding to the exodomain of
the receptor. To understand this, the role of exoloop 2 on the modulation of high affinity
hormone binding to the exodomain was studied using photoaffinity labeling technique.

Meena Sundaramoorthy
20 May 20, 2002

MODULATION OF HIGH AFFINITY HORMONE BINDING TO LH/CG
RECEPTOR

By
Meena Sundaramoorthy

Professor Tae. H Ji
Director of Thesis
Professor Robert Guthrie
Director of Graduate Studies
20 May 20, 2002

RULES FOR THE USE OF THESES

Unpublished theses submitted for the Master's degree and deposited in the University of
Kentucky Library are as a rule open for inspection, but are to be used only with due regard to the
rights of the authors. Bibliographical references may be noted, but quotations or summaries of
parts may be published only with the permission of the author, and with the usual scholarly
acknowledgements.

Extensive copying or publication of the thesis in whole or in part also requires the consent of the
Dean of the Graduate School of the University of Kentucky.

THESIS

Meena Sundaramoorthy

The Graduate School
University of Kentucky
2002

MODULATION OF HIGH AFFINITY HORMONE BINDING TO LH/CG RECEPTOR

_____________________________________________

THESIS
_____________________________________________

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at the University of Kentucky

By
Meena Sundaramoorthy
Lexington, Kentucky
Director: Professor of Chemistry
Lexington, Kentucky
2002

Copyright by

Meena Sundaramoorthy

2002

This thesis work is dedicated to the love and understanding of my wonderful mom Mrs. Uma and
sweet little sister Ms. Vidhya

ACKNOWLEDGEMENTS

I would like to thank Prof. Tae H. Ji for being my philosopher and guide throughout the
preparation of this thesis. I am thankful for his patience and all the wonderful opportunities he
provided me. Many members of “THE JI LAB” made me feel at home – Myoungkun Jeoung,
Chang Woo Lee, Johann Sohn, Becky and Gail – I am glad that I had the opportunity to know
them all and work with them. My special thanks to Dr. Inhae Ji for her kind and encouraging
words at the time of need.
I would like to thank the other members of my advisory committee, Profs. Allan D. Butterfield
and Boyd E. Haley for all their efforts towards making me understand myself better.
I would also like to acknowledge the commitment and support of my husband Rajagopal
Srirangam, without him, this would not have been possible.
Finally, I owe my mom Uma and sister Vidhya, a great big thank you for a lifetime of support
and encouragement in all of my undertakings, academic and otherwise that has meant the world
of difference.

iii

TABLE OF CONTENTS

Acknowledgements

iii

List of Tables

vi

List of figures

vii

List of files

ix

Chapter I: Introduction

1

A. Biology of hCG and Glycoprotein hormones
B. Receptors
1. G protein coupled receptors
2. Structure of LH/CG receptor

3
7
7
14

Chapter II: Materials and Methods

20

A.Radioiodination
1.Radioiodination of peptide
2. Radioiodination of hCG

21
21
22

B. Photoaffinity Labeling

24

C. Affinity Crosslinking

27

D. SDS-PAGE

28

E. Deglycosylation and Glu-C digestion
1. Deglycosylation of iodinated hCG
2. Deglycosylation and Glu-C digestion of
iodinated hCG photoaffinity labeled with peptide

30
30
32

Chapter III: Results and Conclusion

33

A. 1. Radioiodination of peptide
2. Radioiodination of hCG

33
35

B. Exoloop 2 modulates hormone binding to
LH/CG receptor

36

C. Deglycosylation of hCG and Glu-C digestion of

40

iv

hCG photoaffinity labeled with Bpa peptide

Appendix: List of Abbreviations

43

References

44

Curriculum vitae

48

v

LIST OF TABLES
Table 1, G Protein Coupled Receptors……………………………………………………………9

vi

LIST OF FIGURES
Figure 1

Schematic representation of GPCR………………………………….

2

Figure 2

hCG Crystal Structure…………………………….………………….

4

Figure 3

Graafian Follicle…………………………………………………… ...

5

Figure 4

Menstrual Cycle…………………………………………………….…

7

Figure 5

LH/CG Receptor………………………………….………………….

14

Figure 6.a. Ternary Complex……………………………….……………………

15

Figure 6.b. GPCR cell signaling…………………………….…………………...

16

Figure 7

Leucine rich repeat……………………………….…………………….

17

Figure 8

Comparison of Exoloop 2 sequence among different species……….…

19

Figure 9

Computer models of Exoloop 2…………………………………….…..

20

Figure 10

Diagramatic Representation of Photoaffinity Labeling………….……

24

Figure 11

Structure of NHS-AB…………………………………………….……

25

Figure 12

Structure of Bpa………………………………………………………

26

Figure 13

Structure of SES………………………………………………………

27

Figure 14

Structur eof SDS…………………………………………………….…

29

Figure 15

General Schematic Representation of SDS-PAGE……………………

30

Figure 16

Glycosylation site sin Glycoprotein hormones………………………...

31

Figure 17

Iodination of LHR484-503 F493Bpa……………………………………...

34

Figure 18

Radioiodination of NHS-AB Exoloop 2 Peptide……………………….

35

Figure 19

Iodination of hCG………………………………………………………

36

Figure 20

Photoaffinity Labeling of Exoloop 2 Bpa peptide……………………...

37

Figure 21

Photoaffinity Labeling of LHR96-115 S104Bpa and C106Bpa peptide…

38

vii

Figure 22

Photoaffinity Labeling of NHS-AB exoloop 2 peptide………………..

39

Figure 23

Deglycosylation of hCG……………………………..…………………

40

Figure 24

Glu-C digestion of deglycosylated hCG………………………………..

41

Figure 25

Glu-C digestion of hormone incubated with peptide……………………

42

viii

LIST OF FILES
File name

File size

Thesis.pdf

2.03MB

ix

Chapter I
Introduction

G protein coupled receptors ( GPCRs ) constitute the largest and the most diverse membrane
proteins involved in signal transduction. Approximately 1% of the human genome encodes for
these G protein coupled receptors (1). The Luetinizing hormone
receptor belongs to a subfamily of glycoprotein hormone receptors within the GPCR family that
include the receptors for FSH, TSH and hCG. hCG is structurally very similar to LH and binds
with high affinity to the LHR and hence the receptor is referred to as LH/CGR. Both the
LH/CGR and the FSH-R play crucial role in the reproduction of humans. Human reproduction
has been a major worldwide concern. There are countries that suffer from the population
explosion whereas other countries wherein families suffer from infertility and mutations of the
receptors result in hereditary reproductive disorders (2). Understanding the interaction of the LH
and hCG with the LH/CGR would help in the development of drugs that can be used to solve
such problems. GPCRs account for ~ 40% of all therapeutic intervention and major GPCR
research projects are found in the pharmaceutical industry(2,3).

Glycoprotein hormones LH, FSH, TSH and hCG are the most complex agonists for GPCRs. The
LH and hCG both bind to the LH receptor while the FSH and TSH have their own cognate
receptors. GPCRs are activated by a wide variety of ligands including odorant molecules, light,
peptide and nonpeptide neurotransmitters, hormones and growth factors. These glycoprotein
hormones are heterodimers with a common α subunit and a hormone specific β subunit(4). LH
and FSH act together to regulate gonadal functions. They are involved in the growth and
functions of the testis and ovaries and regulation of gametogenesis and steriodogenesis(5).

GPCRs have an extracellular N-terminal domain and a membrane associated C-terminal domain
that consists of seven transmembrane helices connected by three exoloops, three cytoloops and a
cytoplasmic tail (fig 1).
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Figure 1. Schematic representation of GPCR
The general structure of the seven transmembrane GPCR .
Adapted from Ji, T. H., Grossmann, M., and Ji, I. (1998) J. Biol.Chem., 273, 17299-17302

They are coupled to heterotrimeric G proteins and hence are referred to as G protein coupled
receptors. Upon hormone binding, the hormone/receptor complex undergoes a conformational
change and activates G protein to replace GDP with GTP in the Gα subunit. This brings about
the activation of adenylyl cyclase and phosholipase C that results in the formation of the second
messengers, cAMP and IP3, respectively. These second messengers then bring about a lot of
other cellular responses.

The LH/CGR consists of two equal halves, a 341 amino acids long extracellular N terminal half
and a 334 amino acids long membrane associated C terminal half, which includes the seven
transmembrane domains connected by three exoloops and three cytoloops(6,7). In addition, it has
a signal peptide of 26 amino acids.The molecular weight of mature, lacking the signal peptide,
LH/CG-R polypeptide is calculated to be ~75,000 Daltons. However, the actual molecular
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weight is ~85,000 Daltons due to N-glycosylation at 6 Asn residues in the exodomain. The
endodomain is palmitoylated and phosphorylated and their roles are not fully defined.

The exodomain alone is capable of high affinity hormone binding, which is modulated by the
endodomain(8,9). This suggests that the exodomain, in particular the hormone contact sites, and
the endodomain are intimately related to each other during the initial and secondary interactions.
The exodomain, endodomain and the hormone ternary complex is essential for signal generation
(10). However the precise hormone contact points in the exodomain and the endodomain are
unclear. The hormone binding to the exodomain was improved when the endodomain was
truncated (11-13). This suggests that the endodomain influences the hormone binding to the
exodomain. Furthermore, the hCG appears to interact with the exoloop 2 of the LH/CGR (14).
Ala scanning of the 20 amino acids of the exoloop 2 showed that the exoloop 2 indeed influences
the binding of the hormone to the exodomain (9). The aim in the present work was to gain
insight into the molecular basis of hCG binding to its receptor and how the binding is modulated
by the exoloop 2, and whether hCG binds to the exoloop 2 using photoaffinity labeling.

Biology of hCG and Glycoprotein hormones

Gonadotropins comprise of Follicle Stimulating hormone (FSH), Luteinizing hormone (LH),
human Chorionic gonadotropin (hCG) and Thyroid Stimulating hormone (TSH). FSH, LH and
TSH are secreted by the anterior pituitary gland, whereas the trophoblast cells of the human
placenta produce hCG. hCG prevents the deterioration of the corpus luteum and thus is essential
for the maintenance of pregnancy. These hormones are heterodimers with a common α subunit
and a hormone specific β subunit (4). These two subunits are non-covalently associated and are
encoded by distinct genes (15). High-resolution structures of hCG have been reported (16-18)
and are considered as paradigms for the entire glycoprotein hormone family. Each subunit in
these heterodimers is folded into three loops (α1,α2,α3; β1,β2, β3) that project from a cystine
knot located in the center. The unique β subunit of hCG has a seatbelt structure formed by an
intramolecular disulphide bridge (Cys26-Cys110) that embraces the α2 (fig 2).
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hCG α subunit

hCG β subunit

hCG α & β subunit

Figure 2. hCG Crystal structure
Adapted from Lapthorn, A.J., Harris, D.C., Littlejohn, A., Lustbader, J.W., Canfield, R.E., Machin, K.J., Morgan,
F.J. & Isaacs, N.W. (1994) Nature 369, 455–461

There have been numerous studies on which subunits of the hormones are involved in receptor
binding and biological activities. Photoaffinity labeling studies and immunological experiments
have demonstrated that both of the α and β subunits interact with the receptors . When hCG
radioiodinated at either the α or β subunit were incubated with the porcine granulose cells, it
was shown that a complex formed with the LH/CG receptor regardless of whether the hormone
was labeled in the α or β subunit after photoaffinity labeling (19). Monoclonal antibodies
against the α or the β subunit blocked the formation of the LH/CG R complex, suggesting that
both subunits of hCG are involved in binding to the receptor. Both of the gonadotropins subunits
are highly glycosylated with asparagines-linked (N-linked) and/or serine-linked (O-linked)
oligosaccharides (20-23). The common α subunits are N-glycosylated at two conserved sites in
FSH and CG, and one in LH. Unlike other gonadotropins, the hCG β subunit has four additional
O-glycosylation sites (22). The importance of carbohydrates on the glycoprotein hormones have
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been implicated in the hormonal stability, secretion, assembly, receptor binding and
steroidogenesis. When carbohydrates are removed from hCG by anhydrous hydrogen fluride
(HF), the resulting dg-hCG fully maintained its receptor binding and immunological activities
but lost its cAMP and progesterone inducibilities (24-26).

Function of Gonadotropins:

In females gonadotropins control the development of the ovarian follicles, the release of oocytes
from the follicles and the transformation of the ovulated follicles into the corpus lutea (27-29).
Follicles consist of an outer layer of theca interna cells, an inner layer of granulose cells and an
oocyte-cummulus complex (fig 3). Diverse communications between these follicular cells and
the pituitary gland, via gonadotropins, steriodogenesis and production of gonadal peptides,
maintain the continous development of follicles in a cyclic pattern.

Figure 3. Graafian follicle
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During the normal cycles of follicular development, ovulation occurs in two phases- Follicular
phase and Luteal phase (fig 4). The early follicular phase is characterized by high levels of FSH
and low levels of LH, estradiol and progesterone, which are related to the pulsative secretion of
hypothalamic gonadotropin releasing hormone (GnRH) (29-31). FSH activates its receptor,
which is present in granulosa cells of the ovarian follicles, causing an elevated level of cAMP in
the cytosol (32). This signal is largely responsible for stimulating follicular growth, controlling
up- and down- regulation of FSH receptor levels, stimulating the activity of aromatases to
synthesis estradiol and inducing LH/CG receptor expression (32,33). The LH/CGR is present on
both theca and granulose cells. Theca cells produce androstenedione, an androgen precursor,
from cytoplasmic cholesterol, which is regulated by LH and cAMP levels (27). Androstenedione
diffuses into granulose cells and is aromatized into estrogens. The aromatase activity in the
granulose cells is regulated by FSH in immature follicle, and by both LH and FSH in mature
follicles (34). Both cells contain progesterone which is secreted or used as the precursor of
estrogens.

By the mid to the late follicular phase, estradiol secretion is increased and FSH secretion is
suppressed. The increased estradiol and progesterone levels in plasma results in markedly
increased secretion of LH. This LH surge triggers granulose cell disaggregation and subsequent
release of the ovum. After ovulation both the granulosa and theca cells are luteinized to form the
corpus luteum. The corpus luteum is rich in LH/CGR and produce mainly progesterone in a LH
dependent manner (28). In normal menstrual cycle, the corpus luteum functions from 12 to 16
days and then regresses.

In a fertile cycle, hCG secreted from the syncytiotrophoblast maintains the corpus luteum
function by sustaining the plasma levels of estradiol and progesterone through cAMP mediated
protein kinases (35, 36). The hormone is detected a few days after implantation (37). The hCG
levels reach their highest level in plasma at about 10-12 weeks (100,000mIU/mL) and decrease
during the second and third trimesters (38). hCG also induces relaxin secretion from corpus
luteum in the early stages of pregnancy, which may play an important role in maintaining
pregnancy.
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When fertilization does not occur, the corpus luteum produces a lower amount of estradiol and
progesterone and becomes regressed during the late luteal phase. This decline in ovarian steroids
leads to an increase in GnRH. GnRH stimulates FSH release, which initiates the next cycle of
follicular maturation.

Figure 4. Menstrual Cycle
http://www.wisc.edu/ansci_repro/lec/lec_11/lec11fig.html#figure 5

Receptors

G protein coupled receptors:

Nearly 2000 GPCRs have been reported since bovine opsin was cloned in 1983 (39). They are
classified into over 100 subfamilies according to the sequence homology, ligand structure and
receptor function. All GPCRs contain seven transmembrane spanning regions with their Nterminal segment on the exoplasmic side and their C-terminal segment facing the cytosolic side
of the plasma-membrane. Binding of a ligand to a GPCR causes a conformational change that
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allows the receptor to bind to specific G proteins. The activated G protein stimulates enzymes
like adenylyl cyclase, which produces second messengers that bring about cellular responses.
GPCRs are involved in the recognition and transduction of messages as diverse as photons, Ca
2+

, neurotransmitters, biogenic amines and small molecules including amino acids, peptides,

nucleotides as well as proteins. The size of the ligands ranges from 35kD to less than a few 100
daltons. Interestingly, a weak correlation exits such that the larger the ligand, the longer the Nterminal extension of the receptor. For example, the N-terminal extensions of the glycoprotein
hormone receptor are the largest with approximately 300 amino acids, in comparison to the 1130 amino acids long N-terminal extensions of adrenergic receptors (40).

A vast number of biological receptors that are coupled to G proteins have been cloned and
characterized (table I). All these receptors have in common a central core of seven
transmembrane helices connected by three exoloops and three cytoloops. Two cysteine residues
(one in exoloop 1 and other in exoloop 2) are conserved in most GPCRs, form a disulfide bond,
which might be involved in the stabilization of a conformation of the domains that is required for
its activity. Each of the seven transmembrane helices is generally composed of 20-27 amino
acids, while the N-terminal segment (7-595 amino acids), loops (5-230 amino acids) and Cterminal segment (12-359 amino acids) vary in size indicating their diverse structures and
functions.

Glycoprotein hormone receptors:

The glycoprotein hormone receptors consists of two roughly equal halves, a 350-400 amino acid
N-terminal segment and an approximately 300 amino acid membrane associated segment. The
N-terminal half alone is capable of high affinity hormone binding, whereas the membrane
associated half is the site of receptor activation and signal generation (8). The N-terminal domain
has 8-9 Leu-rich repeats. These Leu-rich repeats are thought to form a crescent with the concave
inner surface consisting of β sheets, which may bind ligands (41, 42). In addition to the Leu-rich
crescent, the N-terminal region of the N-terminal segment contacts the hormone (43). Although
the N-terminal segment alone is capable of high affinity ligand binding, this is modulated by
exoloops of the receptor (44).
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Existing evidence suggests that glycoprotein hormones initially bind to the exodomain of the
receptor with high affinity and hormone specificity and then the hormone-receptor complex is
thought to interact with the endodomain of the receptor which then brings about signal
generation.

LH/CG receptor:

Figure 5. LH/CG Receptor

LH/CG-R is encoded by a single copy gene in rats (45) and two genes in humans (46). It is found
mainly in the gonads but also in other organs and tissues like brain, thyroid, prostate, uterus,
placenta, fallopian tubes, fetal membranes and lymphocytes (47). LH/CG-R was also observed in
benign breast region lesions, malignant breast tumors and other cancer cells. Unlike most G
protein coupled receptors, it is comprised of an extremely long extracellular N-terminal half of
341 amino acids and a membrane associated C-terminal half of 334 amino acids (6,7) (fig 5).
The endodomain is palmitoylated and phosphorylated and their roles are not fully defined. Using
photoaffinity labeling studies with receptor peptides, it has been shown that both halves of the
receptor have hormone contact points. The N-terminal half alone is capable of affinity hormone
binding (11-13) with no hormone action (13,48). In contrast, the C-terminal half is capable of
low affinity hormone contact with cAMP induction (13,48).
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Figure 6.a. Ternary complex
Adapted form Ji, T.H., Grossmann, M., and Ji, I. (1998) J. Biol.Chem., 273, 17299-17302

The exodomain binds the hormone with high affinity without hormone action but cannot
generate hormone signal. Growing evidence suggests that glycoprotein hormone initially bind to
the exodomain and the resulting exodomain-hormone complex undergoes conformational change
(49) and interacts with the endodomain of the receptor (fig 6.a.). This secondary interaction is
thought to generate signal (8,50-51). However the high affinity hormone binding at the
exodomain is modulated by the endodomain (52). The LH/CG-R generates two distinct signals,
one to activate adenylyl cyclase and produce cAMP and the other to activate Phospholipase C
and produce diacylglycerol and inositol phosphates (Fig 6.b.). Despite the importance, only
limited information is available concerning the precise hormone contact residues and sites in the
exodomain.
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Figure 6.b. GPCR Cell Signaling

Studies involving truncation, deletion and site-directed mutagenesis indicate that several regions
of the exodomain are crucial for hormone binding. Sequence comparison and modeling suggest
that the exodomain contains Leu/Ile rich repeats (LRRs) (6), which are flanked by short Nterminal and C-terminal regions (fig7). LRRs are a structural motif in proteins like ribonuclease
inhibitor and also common in a large family of proteins. Based on the structure of the
ribonuclease inhibitors, an issue was raised that the inner lining of the LRRs in LH/CG-R and
FSHR might contact the respective hormones (42,53-55), in particular, with the concave side of
the hormone (16). It was shown that the β strand Leu and Ile residues in all LRRs in the human
LHR and FSHR are crucial contact sites (56), especially the LRR2 and LRR4 are important for
hormone binding. Affinity labeling studies showed that the N-terminal region of the LRR4

16

interacts with hCG, preferentially the α subunit and the hCG/LRR4 complex interacts with the
exoloop 2 of the endodomain (67).

The seven to nine Leu-rich repeats in the exodomain, are generally thought to form 1/3 donutlike structure and interact with the hCG. The resulting hCG –exodomain complex then interacts
with the endodomain (exoloop 2) which is results in the signal generation.
But it was unclear whether this alone could be sufficient for the hormone action. To address this,
first residues in the exon 9-10 junction of LHR, junction sequences of FSHR and TSHR were
aligned. A homology was found from Tyr 253 to Phe 260. In addition, the sequence corresponding
to LHR Arg 261 to Gln 268 is highly conserved within each receptor type among species. So, the
exodomain was Ala scanned and receptor peptides were used for photoaffinity labeling and
affinity cross-linking.

Figure 7. Leucine rich repeat
Adapted from Jeoung, M., Phang,T., Song, Y., S., Ji, I and Ji T., H (2001) J. Biol. Chem. 276, 3443-3450

It was shown that the C-flanking sequence (the hinge region), Thr250 – Gln 268 (58) of the LRRs
specifically interacts with hCG, preferentially hCGα. This interaction was shown to be inhibited
by exoloop 2 and not by exoloops 1 and 3. This suggested the importance of the ternary complex
that exists between the exodomain of the receptor, hCG and the endodomain of receptor (59).
Thus the endodomain was seen to modulate the hormone binding to the exodomain. Further a

17

defined epitope on the hCG was shown to interact with the exoloop 2 of the LH/CG-R (14). Ala
scanning of the 20 amino acids of the exoloop 2 showed that the exoloop 2 indeed influences the
binding of the hormone to the exodomain (52).

Both the LH/CG-R and FSHR play crucial role in the reproduction of humans. Human
reproduction has been a major worldwide concern. Approximately 16% of the American families
experience infertility problems and mutations of these receptors result in hereditary reproductive
disorders. Therefore, these hormones and LH/CG-R have been implicated for the treatment of
fertility and infertility disorders. GPCRs account for ~ 40% of all therapeutic intervention and
major GPCR research project are found in the pharmaceutical industry (2,3)

The wealth of information gained over the last decade has substantially improved our
understanding of GPCR function. However the precise identification of the regions of hormone
and receptors that are capable of interaction and /or triggering transmembrane signaling remains
incomplete (60). The further clarification of these mechanisms represents a daunting task
coupled with efforts aimed at obtaining high-resolution X-ray crystals.

The high affinity hormone binding to the N terminal extracellular domain of the GPCR and the G
proteins activated by the intracellular regions of the receptors suggests that upon hormone
binding, a portion of the hormone or the receptor’s extacellular regions might interact with the
exoloops of the GPCRs in ligand binding. The possibility of hormone-receptor interaction
through the exoloops of GPCRs has already been reported. The exoloop 2 of the LH/CGR
consisting of 20 amino acids connects the TM 4 and TM 5 domains. The sequence alignment is
as shown in fig8. The 20 amino acids sequence
Ser484 – Asn485 – Tyr486 – Met487 – Lys488 – Val489 – Ser490 – Ile491 – Cys492 – Phe493 – Pro494 –
Met495 – Asp496 – Val497 – Glu498 – Thr499 – Thr500 – Leu501 – Ser502 – Gln503, is highly conserved
among different species suggesting its importance.
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Fig8.Comparison of exoloop 2 sequences among different species

order to identify the amino acid residues that are crucial for the hormone binding and signal
generation Ala scanned the 20 amino acids long exoloop 2. They found that the high affinity
hormone binding at the exodomain is constrained by the amino acids Ser484, Asn485, Lys488,
Ser490 and Ser499 (61). As a result of this, the exodomain attains maximal affinity for hormone
binding when the endodomain is truncated and cAMP induction is disengaged. It also
demonstrated that exoloop 2 of LH/CG R influences the hormone binding affinity, the affinity
for cAMP induction and maximal cAMP production, probably by the interaction of the exoloop
2 with the exodomain and other parts of the endodomain like the TM 6 and TM 7.

However, one may raise an issue as to whether the Ala substitution effects were due to the
changes in the overall structure of the receptor rather than the changes in the structure close to
the substituted residues. But there is growing evidence that support local conformational changes
induced by substitution of a single amino acid. The Cys residue in the exoloop 2, Cys492 is highly
conserved among the different species and it has been implicated to form a disulphide bridge
with the Cys416 present in exoloop 1, in other GPCRs (62). However, in LH/CG R the C492A
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substitution resulted in the loss of surface expression but not the high affinity hormone binding.
This shows that the Cys residue in exoloop 2 is involved in surface expression but is not
important for hormone binding. Computer modeling suggests that Ser484, Asn485, Lys488, Ser490
and Ser499 may be positioned on one side of exoloop 2. Two models were constructed (fig9). In
both models these residues are clustered together in the middle of the exoloop 2 suggesting their
role in binding affinity.

Figure 9. Computer models of exoloop 2
Adapted from Ryu K-S, Beauchamp J, Tung C-S, Isaacs NW, Ji I, Ji TH.(1998) J. Biol. Chem. 273, 62856291

All these results support the significance of exoloop 2 in the modulation of the hormone binding
to the exodomain of the LH/CG R. The next question is whether or not the crucial exoloop 2
actually interacts with the hormone. To test if the region actually interacts with the hormone,
hCG was photoaffinity labeled with a peptide mimic corresponding to Ser484 – Gln503 of the
receptor.
Chapter II
Materials and Methods
Materials:
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The N-hydroxysuccinimide (NHS) ester of 4-azidobenzoic acid (AB) was synthesized as
described previously (63). The N-hydroxysulfosuccinimide esters of ethylene
glycobis(sulfosuccinimidyl succinate) (SES) was purchased from Pierce. hCG CR127 and
hCG subunits were supplied by the National Hormone and Pituitary Program. Receptor
peptides were synthesized and N-acetylated and C-amidated by Biosynthesis (Lewisville,
TX). They were purified on a Vydac C18 high performance liquid chromatography column
using a solvent gradient from 100% of 0.1% trifluoroacetic acid in water to 20% of 0.1%
trifluoroacetic acid in water and 80% 1-propanol. The peptide mimics include the wild type
receptor peptide corresponding to the LHR sequence of 484-503 (exoloop 2), 246-269 (hinge
region) and receptor peptides in which one of the amino acid residue was substituted by Bpa
like LHR484-503 F493Bpa, LHR96-115 C106Bpa, LHR96-115 S104Bpa and LHR96-115
G109Bpa. All these were purchased from Genemed Synthesis Inc. South San Francisco
California, USA.

Radioiodination

Introduction:
Radioiodination remains one of the extensively used methods for labeling compounds of
medical and biological interest. The radionuclide I125, with its 60 days half-life, has been the
radionuclide of choice for producing labeled compounds for in vitro assays (63). Among
several reactions used for I125 labeling, the Chloramine-T (N-chloro-p-toluenesulfonamide)
oxidation, developed by Hunter and Greenwood in 1962 (64), has proven to be the method of
choice for various compounds containing tyrosyl residues. Thus effective radioiodination can
take place in many compounds and Chloramine labeling often results in biomolecules with
high specific activities. The principle of labeling is based on the “in situ” oxidation of iodide
to atomic iodine and its nucleophilic substitution into phenol rings in ortho position located
in the hydroxyl group of tyrosyl residues of proteins. However, damage to target molecules is
a matter of concern while using this radiolabeling technique.

Reagents:
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Sodium iodide-125 (I125) was purchased from Amersham Pharmacia Biotech, UK.
Chloramine-T was purchased from Sigma (Sigma Chemical Company, St. Louis, MI, USA)
and stored in a dry place at room temperature. Shortly before labeling, a stock solution was
prepared at a concentration of 1mg/mL in 10mM Na2HPO4 and 0.9% NaCl (pH 7.4) (PBS).
Sodium metabisulfite stock solution was also prepared at a concentration of 2.5mg/mL in
PBS that was used as a reducing agent to stop the reaction. The target peptides were
dissolved in 0.1M sodium phosphate (pH 7.5) at a concentration of 30ug/40uL.

Radiolabeling and reaction conditions
1mCi of Na 125I in 10uL of 0.1M NaOH and 7uL of chloramine-T (1ug/uL) in 10mM
Na2HPO4 and 0.9% NaCl (pH 7.4) was added to 30ug of peptide in 40uL of 0.1 M Sodium
phosphate (pH 7.5). After 20 s, 7uL of sodium metabisulfite (2.5mg/mL) in PBS was
introduced to terminate the radioiodination.

Gel permeation of labeled molecules:
Gel permeation was done to remove unbound I125. For this purpose radioiodinated peptide
solution was mixed with 60uL of 16% sucrose solution in PBS and fractionated on Sephadex
Superfine G-10 column (0.6 * 15 cm) previously saturated with elution buffer (PBS). Elution
was done with PBS and the fractions were counted for radioactivity. The specific activity
was calculated.

Derivatization with NHS-AB or SES was done by freshly dissolving the the crosslinking
reagent in dimethyl sulfoxide to a concentration of 50mM in 0.1M sodium phosphate (pH
7.5) to a concentration of 20mM. This reagent solution was immediately used to derivatize
receptor peptides. In the dark, 10uL of NHS-AB or SES was added to the 30ug of peptide in
40uL of 0.1 sodium phosphate (pH 7.5). The mixture was incubated for 30 min with the
cross-linking reagent.
Radioiodination of hCG:
The following protocol is for the radioiodination of hormone only, NOT peptide. It is set up
stoichiometrically such that one I 125 molecule will react with one hormone molecule.
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Reagents:
Sodium iodide-125 (I125) was purchased from Amersham Pharmacia Biotech, UK.
Chloramine-T was purchased from Sigma (Sigma Chemical Company, St. Louis, MI, USA)
and stored in a dry place at room temperature. Shortly before labeling, a stock solution was
prepared at a concentration of 0.3mg/mL in 10mM Na2HPO4 and 0.9% NaCl (pH 7.4)
(PBS). Sodium metabisulfite stock solution was also prepared at a concentration of
0.66mg/mL in PBS that was used as a reducing agent to stop the reaction. The target
hormone was dissolved in 0.1M sodium phosphate (pH 7.5) at a concentration of 3ug/40uL.

Radiolabeling and reaction conditions are similar to radioiodination of peptide and to purify
the iodinated hormone, gel permeation was carried out as described above but on a Sephadex
G-50 superfine column.

Storage:
I125 labeled peptides and hormone were stored in 4° C with the tubes containing
photosensitive peptides wrapped with aluminium foil.
Special Considerations while working safely with I125 (Amersham pharmacia biotech):

1. Freezing or acidification of solutions containing iodide ions can lead to the
formation of volatile elemental iodine.
2. Opening a vial of high radioactive concentration of I125 can produce active aerosols.
3. Some iodo-compounds can penetrate surgical rubber gloves; two pairs or polythene
alternatives are recommended.
4. In the event of suspected contamination of personnel, block the thyroid by the
administration of potassium iodate (170mg) or potassium iodide (130mg).
5. Spills of I125 should be stabilized with alkaline sodium thiosulphate solution before
commencing decontamination.

Although the method is considered easy and reliable, the damage to target molecules due
to excess of oxidant is of major concern. Loss of immunological activity in proteins is
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thought to be due to Chloramine-T action on the disulphide bridges and sulfhydryl
groups, often giving rise to macro molecular protein complexes (64,65). In summary,
radioiodination of biomolecules by the Chloramine-T method is the best method if
excessive use of oxidizing agent is avoided.

B. Photoaffinity labeling:

Photoaffinity labeling is a technique that makes use of capacity of certain compounds to
make covalent bonds after UV irradiation and it overcomes the non-specificity of using
homobifunctional reagents for crosslinking by eliminating random collisional cross-links.
The general protocol for photoaffinity labeling is as shown in the figure 10.

PhotoaffinityLabeling Protocol
Add loading
buffer
Boil samples

Incubate
Expose to
UV

SDS-PAGE

Figure 10. Diagramatic representation of Photoaffinity Labeling

24

Method 1:

Photoaffinity labeling using N-hydroxysuccinimide ester (NHS):

Figure 11. Structure of NHS-AB
To photoaffinity label hCG with 125I-LHR484-503 , the receptor peptide was derivatized with
N-hydroxysuccinimide ester of 4-azidobenzoic acid, (NHS-AB) to produce NHS-AB-125ILHR484-503 as described earlier. Disposable glass tubes were siliconized under
dimethlydichlorosilane vapor for 4 hours and autoclaved. In each of the tubes, 20uL of PBS,
10uL of hCG in PBS (7ng/uL ) and 10uL of AB- 125I-LHR 484-503 (10ng/uL) in PBS were
mixed and incubated at 37°C for 90 min in the dark, irradiated with Mineralight R-52 UV
lamp for 1 min as described previously (66) and solubilized in 2%SDS, 100mM dithiothreitol
and 8M urea to cleave disulfides and dissociate interacting components of complexes. The
samples were electrophoresed on 8-12% polyacrylamide gradient gels. Gels were dried on
Model 583 gel dryer (Bio-Rad), which was exposed to a molecular imaging screen (Bio-Rad)
overnight. The imaging screen was scanned on a Model GS-525 Molecular Imager System
Scanner (Bio-Rad).

Method II:
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Photoaffinity labeling with Bpa as the photoactive group:
A radioiodinatable peptide, LHR484-503, that had a photolabile para-benzoyl-L-phenylalanine
(Bpa) residue at 493 position, instead of the phenylalanine originally present, was used to
photoaffinity label hCG. For this purpose, the Bpa peptide was radioiodinated as described
previously.
Advantages of using Bpa as a photoactivable reagent:
–Excited state is inert towards water
–Chemical stability
–Can be incorporated at a defined position of peptides during synthesis

Figure 12. Structure of Bpa
Adapted from Gyorgy Dorman and Glenn D. Prestwich (1994) Biochemistry, 33,5661-5671

Labeling and reaction conditions:
The following solutions were sequentially introduced into siliconized tubes: 30uL of
radioiodinated Bpa peptide and 10uL of hCG. The mixture was incubated for 90 min at 37° C
in the dark, irradiated with Mineralight R-52 UV lamp for 1 min and solubilized with 2%
SDS, 100mM dithiothreitol and 8M urea to cleave disulfides and dissociate interacting
components of complexes. The samples were electrophoresed on 8-12% polyacrylamide
gradient gels. Gels were dried on Model 583 gel dryer (Bio-Rad) ), which was exposed to a
molecular imaging screen (Bio-Rad) from 24-36 hours depending on the radioactivity present
in the gel. The imaging screen was scanned on a Model GS-525 Molecular Imager System
Scanner (Bio-Rad). The photoaffinity group of choice is p-benzoylphenylalanine (Bpa),
activated at 300-350 nm. However it has to be taken into account that Bpa is a bulky
molecule that can alter the binding of the peptide to receptor. To make a replacement of other
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aminoacid to Bpa, it is better to replace the hydrophobic amino acid in order to try to
preserve the activity.

C.

Affinity crosslinking:

Introduction:
In affinity crosslinking, radioactively labeled ligands are allowed to bind to the receptor and
the resultant ligand-receptor complex, along with all other protein molecules present in the
system, is subject to covalent crosslinks by the introduction of homobifunctional reagents
called crosslinkers. Example of a crosslinker is ethylene
glycolbis(sulfosuccinimidylsuccinate) (SES) also abbreviated as (Sulfo EGS).

Figure 13. Structure of SES
Adapted from www.usalchemy.com

Properties:
1.

M.W. 660.5

2.

Primary amine reactive

3.

Hydroxylamine cleavable

4.

Water soluble

Method:
In siliconized tubes, 20uL of PBS, 10uL of hCG and 10uL of 125 I-LHR 484-503 were mixed
and incubated at 37° C for 90 min. After incubation, 5uL of 0.3mM SES in dimethyl
sulfoxide was added to each tube and further incubated at 25° C for 20 min. The samples
were boiled for 2 min in 2% SDS, 100mM dithiothreitol and 8M urea to cleave disulfides and
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dissociate interacting components of complexes. The solubilized samples were
electrophoresed on 8-12% polyacrylamide gradient gels. The gels were dried on a Model 583
Gel Dryer (Bio-Rad) and exposed to molecular imaging screen (Bio-Rad). The imaging
screen was scanned on a model GS-525 Molecular Imager System Scanner (Bio-Rad).

Advantages and Disadvantages of photoaffinity labeling and affinity crosslinking:

The primary advantage of photoaffinity labeling over affinity crosslinking is that formation
of a covalently crosslinked complex is limited to the ligand and the receptor in photoaffinity
labeling in other words is highly specific, whereas in affinity crosslinking formation of
crosslinked complexes is random and non-specific. However, one major advantage of affinity
crosslinking is the complex is not light sensitive and hence reaction need not be carried out in
the dark.

D.

Sodium dodecyl sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE):

Introduction:

Electrophoresis is the migration of charged molecules in solution in response to an electric
field. Their rate of migration depends on the strength of the field; on the net charge, size and
shape of the molecules and also on the ionic strength, viscosity and temperature of the
medium in which the molecules are moving. As an analytical tool, electrophoresis is simple,
rapid and highly sensitive. It is used analytically to study the properties of a single charged
species, and as a separation technique.

SDS-PAGE:

A technique for analyzing mixtures of proteins or for estimating protein molecular weights,
involving electrophoresis in a polyacrylamide gel in the presence of the anionic detergent,
sodium dodecyl sulphate (SDS). The SDS binds to the proteins, denaturing them and
conferring on them a uniform density of negative charges. The denatured protein / SDS
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complexes show a constant relationship between mobility and log (MW). The molecular
weight of a particular protein can be assessed by comparison of its migration with those of a
series of marker proteins of known sizes.

The pore size of the gel may be varied to produce different molecular seiving effects for
separating proteins of different sizes. In this way, the percentage of polyacrylmide can be
controlled in a given gel. By controlling the percentage (from 3% to 30%), pore sizes can be
modulated, usually to resolve molecules of 5 to 2,000 kdal. This is the ideal range for gene
sequencing, protein, polypeptide, and enzyme analysis. Polyacrylamide gels can be cast in
non gradient or with varying gradients. Gradient gels provide continuous decrease in pore
size from the top to the bottom of the gel, resulting in better defined bands. Because of this
banding effect, detailed genetic and molecular analysis can be performed on gradient
polyacrylamide gels. Polyacrylamide gels offer greater flexibility and more sharply defined
banding than agarose gels.

Figure 14. Structure of SDS
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Figure 15. General Schematic Representation of SDS-PAGE

Method:
The solubilized samples were loaded onto a 8-12% polyacrylamide gradient gel. The
electrophoresis was carried out initially at 60V for 2 hours and then at 100 for 8hours. The
gel was fixed in 33% methanol for 45min and dried using Model 583 Gel dryer (Bio-Rad).

E.

Deglycosylation and Glu C digestion of hCG:
1.Deglycosylation of iodinated hCG:

Introduction:
30

Glycosylation of glycoprotein hormones begins in the rough endoplasmic reticulum (RER).
The figure 16 below shows the glycosylation sites on the human glycoprotein hormone and -subunits. The subunit proteins are indicated by the horizontal bars and the N-linked
oligosaccharides by the branch-like structures. The lollipop indicates O-linked glycosylation
sites in CG . The amino acid residue to which the oligosaccharide is attached is indicated by
the numbers under each glycosylation site.

Figure 16. Glycosylation sites in Glycoprotein hormones
adapted from Arch Med Res. 2001 Nov-Dec;32(6):520-32. Review.)

Oligosaccharide structures of glycoprotein hormones play an essential role in many of the
functional characteristics of the molecule. They are important not only for the folding,
assembly, conformational maturation and posttranslational processing of the subunits but
also for heterodimer secretion, metabolic fate, interaction with cognate receptor and signal
transduction. Chemical or enzymatic treatments to remove the N-glycans on hCG reveal that
removal of the carbohydrate moieties has little effect on receptor binding. So, to check the
binding of hCG without the sugars to LH/CG R, deglycosylation of iodinated hCG was
carried out.
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Materials and Method:

Peptide:N-glycosidase F (PNGase F) was bought from New England BioLabs Inc and OGlycosidase from Roche Diagnostics.
PNGase is an amidase with an apparent molecular weight of 36,000Daltons. It cleaves
between the innermost GlcNAc and Asn residue of high mannose, hybrid and complex
oligosaccharides from N-linked glycoproteins.

O-Glycosiadase is used to release the Gal β (1-3) GalNAc from O-glycans. Bindings to
serine as well as to threonine are hydrolysed.

To 10uL iodinated hCG the following was added, 5uL of 40mM DTT and 10uL of 1M Urea.
The mixture was boiled for 4 min, cooled and then added 2uL of PNGase F and 1uL of OGlycosidase. Incubated the samples for 18 hours at 37° C. The samples were loaded onto
15% polyacrylamide single concentration gel. Gel was dried on a Model 583 gel dryer and
exposed to molecular imaging screen (Bio-Rad) overnight. The imaging screen was scanned
on a Model GS-525 Molecular Imager System Scanner (Bio-Rad).

2. Deglycosylation and Glu-C digestion of iodinated hCG photoaffinity labeled with
peptide:

Introduction:
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Endoproteinase Glu-C cleaves at Glutamic acid – X and Aspartic acid – X where X is any
other amino acid residue. By treating the hCG photoaffinity labeled with peptide for
deglycosylation and further to Glu C digestion, the fragments obtained can be analyzed by
Mass Spectrometry to identify labeled amino acid residues.

Materials and Method:

Glu C was purchased from Roche Diagnostics. The iodinated hCG was incubated with wild
type peptide (LHR96-115 G 109Bpa) for 90 min at 37° C. The samples were irradiated with
Mineralight R-52 UV lamp for 1 min. Added 10uL of 1M urea and 5uL of 20mM DTT to the
above mixture and boiled for 4 min. The sample was cooled down and 8% Glu-C was added
and incubated at room temperature for 16 hours. The samples were solubilized in 2%SDS,
100mM dithiothreitol and 8M urea to cleave disulfides and dissociate interacting components
of complexes and electrophoresed on 15% polyacrylamide single concentration gels. Gels
were dried on Model 583 gel dryer (Bio-Rad), which was exposed to a molecular imaging
screen (Bio-Rad) overnight. The imaging screen was scanned on a Model GS-525 Molecular
Imager System Scanner (Bio-Rad).

Drawbacks of the enzymatics treatments:
1.

The treatments may damage the protein backbone

2.

Removal of the oligosaccharides may be incomplete.

Chapter III
Results and Conclusion
A.1. Radioiodination of peptide:
Radioiodination of compounds by the Chloramine-T method results in biomolecules with high
specific activities. The following figure shows the radioiodiantion of the LHR484-503 F 493 Bpa
peptide. The 125I is incorporated on the Tyrosine, 10 fractions were collected. A sharp peak
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which corresponds to the hottest fraction is number 3 with 408,477cpm/2uL. The specific
activity is 10,667.2 cpm/ng. The fraction number 3 was stored in a glass tube wrapped with
aluminium foil to prevent exposure to light until use.

Fraction
1
2
3
4
5
6
7
8
9
10
Total

CPM
215
125666
408477
188195
148293
118230
116579
104017
98831
82867
1391370

Total cpm = 1391370 * 230
Specific activity = 10667.2 cpm/ng
Fraction 3 has 408477 * 230 = 93949710 cpm
Therefore ng of peptide present in fraction 3 is 8807.3 ng
100ng of peptide is present in 2.6uL of fraction 3
Figure 17. Iodination of LHR484-503 F493Bpa

For photoaffinity labeling using NHS-AB, the derivatized peptide is iodinated.

34

Fraction cpm
1
18872
2 730474
3 708303
4 192148
5 182828
6 118560
7
40551
8
26016
9
12747
10
9733
2040232

CT(0.38umol)=1mg/1mL spb
SM(0.92umol)=2.5mg/1mL spb
SU(16%)= 0.024g/150uL spb
NHS-AB = 0.00065g/50uL
peptide = 30ug/40uL
Flow rate=200uL/4 drops

Total cpm = 2040232 * 200
= 408050000
Specific Activity = total cpm/ng of peptide used
= 408050000/30000
= 13601.5cpm/ng
Specific Activity = 13601.5cpm/ng
Fraction 2 has 730474 cpm
Therefore ng of peptide present is 730474 * 200/ 13601.5
10741ng of peptide is present in fraction 2
100ng of peptide is present in 1.9 uL of fraction 2
100 ng of peptide has 1360160 cpm
Figure 18. Radioiodination of NHS-AB Exoloop 2 Peptide

A.2. Radioiodination of hCG:
Radioiodination of hormone was designed such that only one 125I molecule reacts with one
hormone molecule. Below is the figure showing the results of iodination of hCG. 6 fractions
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were collected. There was a peak with 478016cpm/2uL of fraction 2. This fraction was stored in
a glass tube for further use.

Fraction

CPM
1
2
3
4
5
6

1500
478016
263100
25200
12488
3103

Total cpm = 783407 * 230
Specific activity = 783407 * 230 / 3,000 = 60,061.2 cpm/ng
Fraction 2 has 478016 * 230 cpm = 109,943,680 cpm
Therefore ng of hCG present in fraction 2 is 1830.5ng

Figure 19 Iodination of hCG
B. Exoloop 2 modulates hormone binding to LH/CG receptor:

The LHR484-503 F493Bpa was radioiodinated on Tyr residue in position 486 using Na 125I and
fractionated on a sephadex G-10 column. The peptide was incubated with hCG, exposed to UV
light, solubilized and then separated on SDS-Polyacrylamide gel. Dried gels were analyzed on a
phosphoimager. The hormone concentration dependent, peptide concentration dependent and the
UV duration dependent assays were carried out.
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A

B

C

Figure 20. Photoaffinity Labeling of Exoloop 2 Bpa peptide
hCG was incubated with 125 I-LHR484-503 F493Bpa and irrardiated with UV. In this series, UV irradiation time (C) ,
I-LHR 484-503 F493Bpa concentration ( B ), or hCG concentration (A ) was varied, while the other two factors
were kept constant. After electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a
molecular imaging screen (Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager
System Scanner (Bio-Rad).
125

One major limitation of the Bpa peptide for these studies is that it is photolysable. To determine
the photolysis and overcome this problem the UV duration dependent study was performed,
shown in the figure 20. A striking feature observed in all the experiments performed with the
exoloop 2 Bpa peptide was that in the second lane with no hormone in hormone concentration
dependent assay there is labeling seen. One possible explanation is contamination during loading
the samples onto the gel. For all these assays the first lane is 125I-hCG used as marker. To check
if this was due to some technical error, photoaffinity labeling of S104Bpa and C106Bpa of
LHR96-115 was carried out (fig21). From the figure it is obvious that the α subunit of the hCG
was labeled more than the β subunit. With increasing concentration of hormone, the intensity of
labeling also increased.
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B

A

C106Bpa

S104Bpa

Figure 21. Photoaffinity Labeling of LHR96-115 S104Bpa and C106Bpa peptides

hCG was incubated with 125 I-LHR 96-115 C106Bpa (A) and 125 I-LHR 96-115 S104Bpa (B) and irrardiated with
UV.hCG concentration was varied while the concentration of the peptide and UV irradiation time were kept
constant. After electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular
imaging screen (Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner
(Bio-Rad).

The bands seen in experiments with exoloop 2 Bpa peptide may represent oxidation products that
overshadow the actual labeled α subunit. There are residues in the exoloop 2 that can possibly be
oxidized like methionine and cysteine. One way to eliminate this potential oxidative damage is to
replace these residues with some other amino acid like isoleucine that are resistant to oxidation.
However we cannot exclude the possibility of these amino acid substitutions not affecting the
global structure of the protein or the peptide. Another possible explanation for the diffuse bands
is that the exoloop2 Bpa peptide might dimerize by itself. Compounding this problem is the Bpa
being a highly hydrophobic bulky group. A homobifunctional crosslinker SES was used to
crosslink the radioactively labeled Exoloop 2 Bpa peptide to hCG (diagram not shown).
However since the crosslinking is random, formation of hormone-hormone complexes and
peptide-peptide complexes is also possible.
NHS-AB can reach and label target molecules up to 7° A. 125I-LHR 484-503 derivatized with NHSAB bind to hCG and when irradiated with UV, crosslinking is restricted between 125I-LHR484-503
and hCGα or between 125I-LHR484-503 and hCGβ. The reagent however will not be able to
crosslink one hCG subunit to another. As shown in the figure 22, NHS-AB –125I-LHR484-503 was
38

capable of photoaffinity labeling either hCG α or hCGβ but not both subunits at the same time to
produce hCGαβ complex. In addition hCG α was more preferentially labeled than hCG β. One
possible explanation for this is that the N-terminus of the LHR484-503 derivatives is < 7° A from
the hCG α and β subunits and the peptide derivatives are bound closer to the α than β subunit.

A

B

D

C

Figure 22. Photoaffinity Labeling of NHS-AB exoloop 2 peptide
hCG was incubated with AB-125I-LHR 484-503 and irrardiated with UV. UV irradiation time (C), AB-125 I-LHR 484-503
concentration ( B ), or hCG concentration (A ) was varied, while the other two factors were kept constant. In (D ),
denatured hCG was incubated with increasing concentration of AB-125I-LHR 484-503 and irradiated with UV for 2
min. After electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular
imaging screen (Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner
(Bio-Rad).

Concentration effect of hCG and the peptide:
When a constant amount of hCG was incubated with increasing concentrations of the NHS-AB125

I-LHR484-503, the intensity of the labeled hCG α and β bands increased gradually and plateaued

as shown in the fig22. A similar result was obtained when a constant amount of the peptide was
incubated with increasing concentrations of hCG. These results show that the concentrations of
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both of the peptide and hCG are the limiting factors for the photoaffinity labeling. The labeling
was dependent on the hCG concentration, derivatized peptide and UV exposure and in all cases
the hCG was preferentially labeled. In conclusion, although the NHS-AB derivatized peptide was
shown to label the hCG preferentially the α subunit than the β subunit, the exoloop 2 Bpa
peptide was definitely a tough one to work with and had lots of problems hard to define.
Deglycosylation of iodinated hCG was carried out. Figure 23 shows this. The α band is shifted
much lower when sample sourse treated with a glycosidase and PNGase F, which is in agreement
to the removal of sugar molecules. Glu C digestion of the iodinated hCG after deglycosylation
was also carried out (fig 24). It can be seen that the deglycosylation and the digestion both are
incomplete.

Figure 23. Deglycosylation of 125 hCG
125 I-hCG was solubilized with DTT and urea, treated with PNGase F and O-Glycosidase and incubated. After
electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular imaging screen
(Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner (Bio-Rad).
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Figure 24. Glu-C digestion of deglycosylated hCG
125 I-hCG was solubilized with DTT and urea and in lane 2 treated with PNGase F and O-Glycosidase and
incubated while in lane 3 treated with PNGase F and O-Glycosidase and Glu-C and incubated. After electrophoresis
of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular imaging screen (Bio-Rad). The
imaging screen was scanned on a model GS-525 Molecular Imager System Scanner (Bio-Rad).
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Figure 25. Glu-C digestion of hormone incubated with peptide
hCG was incubated with 125 I-LHR 96-115 G109Bpa (lanes 5 and 6) and 125 I-LHR484-503 F493Bpa (lanes 3 and 4) and
irrardiated with UV. Samples were solubilized with DTT and urea and incubated with Glu-C.
After electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular imaging
screen (Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner (BioRad).

hCG photoaffinity labeled with peptide LHR96-115 G109Bpa or LHR484-503 F493Bpa that was
deglycosylated and digested with Glu-C digestion is shown in figure 25. The first lane is just the
iodinated hCG and second lane shows hCG deglycosylated and then digested with 8% Glu-C. In
the lanes 3 to 6 the 125I hCG labeled with the peptides, and lanes 4 and 6 are the samples treated
with glycosydidase, PNGase F and Glu-C. The lanes 1, 3 and 5 look the same because the
peptide molecular weight is in the order of 2000 Daltons which is negligible when compared to
that of the hCG. The same is the case with lanes 2, 4 and 6, and additional the Glu-C digestion
did not work very well.

Since the deglycosylation and Glu-C digestion work, it will be interesting to analyze the
fragments by Mass Spectrometry.
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Appendix: Abbreviations and Symbols

GPCR

G protein coupled receptor

hCG

human choriogonadotropin

FSH

Follicle Stimulating Hormone

TSH

Thyroid Stimulating Hormone

LH

Luteinizing hormone

GnRH

Gonadotropin releasing hormone

LH/CGR Luteinizing hormone/ Chorionic gonadotropin hormone receptor
FSHR

Follicle Stimulating Hormone Receptor

GTP

Guanine Triphosphate

GDP

Guanine diphosphate

dg-hCG

Deglycosylated human chorionic gonadotropin

cAMP

cyclic Adenosine mono phosphate

Ca 2+

Calcium ions

Asn

Asparagine

Leu

Leucine

LRR

Leucine rich repeats

NHS-AB

N-hydroxysuccinimide ester of amino benzoic acid

Bpa

4-benzoyl phenylalanine

SES

ethylene glycolbis(sulfosuccinimidylsuccinate)

PBS

Phosphate buffered saline

SDS

Sodium dodecyl sulphate

DTT

Dithiothrietol

NaCl

Sodium chloride

Na2HPO4

Sodium Phosphate Dibasic

NaOH

Sodium Hydroxide

UV

Ultra violet
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